Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients

Hiroko Masuda, Norikazu Masuda, Yoshinori Kodama, Masami Ogawa, Michiko Karita, Jun Yamamura, Kazunori Tsukuda, Hiroyoshi Doihara, Shinichiro Miyoshi, Masayuki Mano, Shoji Nakamori, Toshimasa Tsujinaka

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: Triple-negative breast cancers (TNBCs) do not derive benefit from molecular-targeted treatments such as endocrine therapy or anti-HER2 therapy because they lack those molecular targets. On the other hand, TNBCs have been shown to respond to neoadjuvant chemotherapy (NAC). In this study, we analyzed TNBC patients who were treated with NAC at Osaka National Hospital over a recent 5-year period to clarify the predictive factors for NAC and prognostic factors. Patients and methods: Thirty-three TNBC patients underwent sequential NAC with anthracycline (FEC100: 5FU 500 mg/m2, epirubicin 100 mg/m 2, and cyclophosphamide 500 mg/m2/q3w, 4 courses) and taxanes (paclitaxel 80 mg/m2/qw, 12 courses or docetaxel 75 mg/m 2/q3w, 4 courses) from May 2003 to July 2008. Pre-therapeutical and surgical specimens were studied for expressions of ER, PgR, HER-2, EGFR, cytokeratin 5/6, Ki-67, p53 and androgen receptor by immunohistochemistry (IHC). We analyzed clinicopathological factors and molecular markers in regard to the response to NAC and prognosis. Results: Pathological complete response (pCR) was achieved in 12 TNBC patients (36%). The pCR rate in the basal-like phenotype was significantly lower than in the non-basal-like phenotype (23 vs. 64%, respectively: P = 0.02). High pre-operative expressions of Ki-67 (≥50%) and HER-2 (2+) were considered as predictive factors for a better response from NAC. Pre-operative Ki-67 expression showed a significant correlation with disease-free survival (DFS) and a lower expression of Ki-67 (

Original languageEnglish
Pages (from-to)911-917
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume67
Issue number4
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Triple Negative Breast Neoplasms
Chemotherapy
Drug Therapy
docetaxel
Keratin-6
Keratin-5
Phenotype
Taxoids
Epirubicin
Anthracyclines
Androgen Receptors
Paclitaxel
Fluorouracil
Cyclophosphamide
Disease-Free Survival
Therapeutics
Immunohistochemistry

Keywords

  • Basal-like phenotype
  • Ki-67
  • Neoadjuvant chemotherapy
  • Pathological complete response
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. / Masuda, Hiroko; Masuda, Norikazu; Kodama, Yoshinori; Ogawa, Masami; Karita, Michiko; Yamamura, Jun; Tsukuda, Kazunori; Doihara, Hiroyoshi; Miyoshi, Shinichiro; Mano, Masayuki; Nakamori, Shoji; Tsujinaka, Toshimasa.

In: Cancer Chemotherapy and Pharmacology, Vol. 67, No. 4, 04.2011, p. 911-917.

Research output: Contribution to journalArticle

Masuda, H, Masuda, N, Kodama, Y, Ogawa, M, Karita, M, Yamamura, J, Tsukuda, K, Doihara, H, Miyoshi, S, Mano, M, Nakamori, S & Tsujinaka, T 2011, 'Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients', Cancer Chemotherapy and Pharmacology, vol. 67, no. 4, pp. 911-917. https://doi.org/10.1007/s00280-010-1371-4
Masuda, Hiroko ; Masuda, Norikazu ; Kodama, Yoshinori ; Ogawa, Masami ; Karita, Michiko ; Yamamura, Jun ; Tsukuda, Kazunori ; Doihara, Hiroyoshi ; Miyoshi, Shinichiro ; Mano, Masayuki ; Nakamori, Shoji ; Tsujinaka, Toshimasa. / Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. In: Cancer Chemotherapy and Pharmacology. 2011 ; Vol. 67, No. 4. pp. 911-917.
@article{183237164b134827b479ebb5870c4479,
title = "Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients",
abstract = "Purpose: Triple-negative breast cancers (TNBCs) do not derive benefit from molecular-targeted treatments such as endocrine therapy or anti-HER2 therapy because they lack those molecular targets. On the other hand, TNBCs have been shown to respond to neoadjuvant chemotherapy (NAC). In this study, we analyzed TNBC patients who were treated with NAC at Osaka National Hospital over a recent 5-year period to clarify the predictive factors for NAC and prognostic factors. Patients and methods: Thirty-three TNBC patients underwent sequential NAC with anthracycline (FEC100: 5FU 500 mg/m2, epirubicin 100 mg/m 2, and cyclophosphamide 500 mg/m2/q3w, 4 courses) and taxanes (paclitaxel 80 mg/m2/qw, 12 courses or docetaxel 75 mg/m 2/q3w, 4 courses) from May 2003 to July 2008. Pre-therapeutical and surgical specimens were studied for expressions of ER, PgR, HER-2, EGFR, cytokeratin 5/6, Ki-67, p53 and androgen receptor by immunohistochemistry (IHC). We analyzed clinicopathological factors and molecular markers in regard to the response to NAC and prognosis. Results: Pathological complete response (pCR) was achieved in 12 TNBC patients (36{\%}). The pCR rate in the basal-like phenotype was significantly lower than in the non-basal-like phenotype (23 vs. 64{\%}, respectively: P = 0.02). High pre-operative expressions of Ki-67 (≥50{\%}) and HER-2 (2+) were considered as predictive factors for a better response from NAC. Pre-operative Ki-67 expression showed a significant correlation with disease-free survival (DFS) and a lower expression of Ki-67 (",
keywords = "Basal-like phenotype, Ki-67, Neoadjuvant chemotherapy, Pathological complete response, Triple-negative breast cancer",
author = "Hiroko Masuda and Norikazu Masuda and Yoshinori Kodama and Masami Ogawa and Michiko Karita and Jun Yamamura and Kazunori Tsukuda and Hiroyoshi Doihara and Shinichiro Miyoshi and Masayuki Mano and Shoji Nakamori and Toshimasa Tsujinaka",
year = "2011",
month = "4",
doi = "10.1007/s00280-010-1371-4",
language = "English",
volume = "67",
pages = "911--917",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients

AU - Masuda, Hiroko

AU - Masuda, Norikazu

AU - Kodama, Yoshinori

AU - Ogawa, Masami

AU - Karita, Michiko

AU - Yamamura, Jun

AU - Tsukuda, Kazunori

AU - Doihara, Hiroyoshi

AU - Miyoshi, Shinichiro

AU - Mano, Masayuki

AU - Nakamori, Shoji

AU - Tsujinaka, Toshimasa

PY - 2011/4

Y1 - 2011/4

N2 - Purpose: Triple-negative breast cancers (TNBCs) do not derive benefit from molecular-targeted treatments such as endocrine therapy or anti-HER2 therapy because they lack those molecular targets. On the other hand, TNBCs have been shown to respond to neoadjuvant chemotherapy (NAC). In this study, we analyzed TNBC patients who were treated with NAC at Osaka National Hospital over a recent 5-year period to clarify the predictive factors for NAC and prognostic factors. Patients and methods: Thirty-three TNBC patients underwent sequential NAC with anthracycline (FEC100: 5FU 500 mg/m2, epirubicin 100 mg/m 2, and cyclophosphamide 500 mg/m2/q3w, 4 courses) and taxanes (paclitaxel 80 mg/m2/qw, 12 courses or docetaxel 75 mg/m 2/q3w, 4 courses) from May 2003 to July 2008. Pre-therapeutical and surgical specimens were studied for expressions of ER, PgR, HER-2, EGFR, cytokeratin 5/6, Ki-67, p53 and androgen receptor by immunohistochemistry (IHC). We analyzed clinicopathological factors and molecular markers in regard to the response to NAC and prognosis. Results: Pathological complete response (pCR) was achieved in 12 TNBC patients (36%). The pCR rate in the basal-like phenotype was significantly lower than in the non-basal-like phenotype (23 vs. 64%, respectively: P = 0.02). High pre-operative expressions of Ki-67 (≥50%) and HER-2 (2+) were considered as predictive factors for a better response from NAC. Pre-operative Ki-67 expression showed a significant correlation with disease-free survival (DFS) and a lower expression of Ki-67 (

AB - Purpose: Triple-negative breast cancers (TNBCs) do not derive benefit from molecular-targeted treatments such as endocrine therapy or anti-HER2 therapy because they lack those molecular targets. On the other hand, TNBCs have been shown to respond to neoadjuvant chemotherapy (NAC). In this study, we analyzed TNBC patients who were treated with NAC at Osaka National Hospital over a recent 5-year period to clarify the predictive factors for NAC and prognostic factors. Patients and methods: Thirty-three TNBC patients underwent sequential NAC with anthracycline (FEC100: 5FU 500 mg/m2, epirubicin 100 mg/m 2, and cyclophosphamide 500 mg/m2/q3w, 4 courses) and taxanes (paclitaxel 80 mg/m2/qw, 12 courses or docetaxel 75 mg/m 2/q3w, 4 courses) from May 2003 to July 2008. Pre-therapeutical and surgical specimens were studied for expressions of ER, PgR, HER-2, EGFR, cytokeratin 5/6, Ki-67, p53 and androgen receptor by immunohistochemistry (IHC). We analyzed clinicopathological factors and molecular markers in regard to the response to NAC and prognosis. Results: Pathological complete response (pCR) was achieved in 12 TNBC patients (36%). The pCR rate in the basal-like phenotype was significantly lower than in the non-basal-like phenotype (23 vs. 64%, respectively: P = 0.02). High pre-operative expressions of Ki-67 (≥50%) and HER-2 (2+) were considered as predictive factors for a better response from NAC. Pre-operative Ki-67 expression showed a significant correlation with disease-free survival (DFS) and a lower expression of Ki-67 (

KW - Basal-like phenotype

KW - Ki-67

KW - Neoadjuvant chemotherapy

KW - Pathological complete response

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=79954434628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954434628&partnerID=8YFLogxK

U2 - 10.1007/s00280-010-1371-4

DO - 10.1007/s00280-010-1371-4

M3 - Article

C2 - 20593180

AN - SCOPUS:79954434628

VL - 67

SP - 911

EP - 917

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -